Ipek Özer Stillman - Concepedia

Author

Ipek Özer Stillman

Harvard University

Also Known As

I Ozer Stillman, I. Ozer Stillman, I.O. Stillman, Ipek Ozer Stillman, Ipek Stillman, Ipek Özer Stillman

Publications

928

Citations

H-Index

Concepts

All Affiliations

Harvard University Takeda (United States)University of Pikeville Ithaka Harbors Massachusetts Eye and Ear Infirmary

IÖ

About

Ipek Özer Stillman is an author at Harvard University specializing in public health, outcomes research, and health policy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	23
2	Public Health	1	1	23
3	Health Policy	1	1	23
4	Risk	1	1	23
5	Cardiometabolic Risk	1	1	23

Ipek Özer Stillman

Publications

906

Citations

H-Index

Page 1

	Year	Citations
Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older Kimberly F Farrand, Moshe Fridman, Ipek Özer Stillman, American Journal of Ophthalmology	2017	534
Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System Reza Dana, John L. Bradley, Annie Guérin, American Journal of Ophthalmology	2019	219
<p>Dry eye disease ranking among common reasons for seeking eye care in a large US claims database</p> John L. Bradley, Ipek Özer Stillman, Irina Pivneva, Clinical ophthalmology	2019	63
Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study Reza Dana, John L. Bradley, Annie Guérin, American Journal of Ophthalmology	2018	31
Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model J. Jaime, Ipek Özer Stillman, A Danel, Journal of Medical Economics Cardiometabolic RiskPreventive CardiologyMarkov ModelPublic HealthHealth Services Research	2007	23
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US Catherine Saint‐Laurent Thibault, Ipek Özer Stillman, Stephanie Chen, Journal of Medical Economics	2015	20
Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia John Whalen, Ipek Özer Stillman, Apoorva Ambavane, Journal of Medical Economics	2015	16

Page 1